This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2021 Apr 15;384(15):1471-1473.

doi: 10.1056/NEJMc2102961.

Cardiovascular Outcomes with Sotagliflozin. Reply

Deepak L Bhatt¹, P Gabriel Steg², Bertram Pitt³

Affiliations

Affiliations

¹ Harvard Medical School, Boston, MA dlbhattmd@post.harvard.edu.
² Université de Paris, Paris, France.
³ University of Michigan, Ann Arbor, MI.

PMID: 33852788
DOI: 10.1056/NEJMc2102961

Comment

Cardiovascular Outcomes with Sotagliflozin. Reply

Deepak L Bhatt et al. N Engl J Med. 2021.

. 2021 Apr 15;384(15):1471-1473.

doi: 10.1056/NEJMc2102961.

Authors

Deepak L Bhatt¹, P Gabriel Steg², Bertram Pitt³

Affiliations

¹ Harvard Medical School, Boston, MA dlbhattmd@post.harvard.edu.
² Université de Paris, Paris, France.
³ University of Michigan, Ann Arbor, MI.

PMID: 33852788
DOI: 10.1056/NEJMc2102961

No abstract available

PubMed Disclaimer

Comment on

Cardiovascular Outcomes with Sotagliflozin.
Baglioni P. Baglioni P. N Engl J Med. 2021 Apr 15;384(15):1470-1471. doi: 10.1056/NEJMc2102961. N Engl J Med. 2021. PMID: 33852786 No abstract available.
Cardiovascular Outcomes with Sotagliflozin.
Marchand L, Villar E, Green L. Marchand L, et al. N Engl J Med. 2021 Apr 15;384(15):1471. doi: 10.1056/NEJMc2102961. N Engl J Med. 2021. PMID: 33852787 No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations